343 related articles for article (PubMed ID: 28941158)
1. Prognostic and predictive role of [
Zucali PA; Lopci E; Ceresoli GL; Giordano L; Perrino M; Ciocia G; Gianoncelli L; Lorenzi E; Simonelli M; De Vincenzo F; Setti LR; Bonifacio C; Bonomi M; Bombardieri E; Chiti A; Santoro A
Cancer Med; 2017 Oct; 6(10):2287-2296. PubMed ID: 28941158
[TBL] [Abstract][Full Text] [Related]
2. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA
Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.
Lopci E; Zucali PA; Ceresoli GL; Perrino M; Giordano L; Gianoncelli L; Lorenzi E; Gemelli M; Santoro A; Chiti A
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):667-75. PubMed ID: 25403555
[TBL] [Abstract][Full Text] [Related]
4. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma.
Veit-Haibach P; Schaefer NG; Steinert HC; Soyka JD; Seifert B; Stahel RA
Lung Cancer; 2010 Mar; 67(3):311-7. PubMed ID: 19482372
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of F18 Fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy - A prospective cohort study.
May IJ; Nowak AK; Francis RJ; Ebert MA; Dhaliwal SS
J Med Imaging Radiat Oncol; 2024 Feb; 68(1):57-66. PubMed ID: 37898984
[TBL] [Abstract][Full Text] [Related]
6. The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma.
Klabatsa A; Chicklore S; Barrington SF; Goh V; Lang-Lazdunski L; Cook GJ
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):276-82. PubMed ID: 24057459
[TBL] [Abstract][Full Text] [Related]
7. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
Kanemura S; Kuribayashi K; Funaguchi N; Shibata E; Mikami K; Doi H; Kitajima K; Hasegawa S; Nakano T
Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
9. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
Sharif S; Zahid I; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):806-11. PubMed ID: 21266493
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of pretreatment volume-based quantitative
Kitajima K; Doi H; Kuribayashi K; Hashimoto M; Tsuchitani T; Tanooka M; Fukushima K; Nakano T; Hasegawa S; Hirota S
Eur J Radiol; 2017 Jan; 86():176-183. PubMed ID: 28027744
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
[TBL] [Abstract][Full Text] [Related]
12. Histology of the pleural rind at [
Soltermann A; Opitz I; Burger IA
Pathol Res Pract; 2021 Dec; 228():153660. PubMed ID: 34749212
[TBL] [Abstract][Full Text] [Related]
13. FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients.
Incerti E; Broggi S; Fodor A; Cuzzocrea M; Samanes Gajate AM; Mapelli P; Fiorino C; Dell'Oca I; Pasetti M; Cattaneo M; Calandrino R; Gianolli L; Di Muzio N; Picchio M
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2071-2078. PubMed ID: 29876617
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.
Zaizen Y; Azuma K; Kurata S; Sadashima E; Hattori S; Sasada T; Imamura Y; Kaida H; Kawahara A; Kinoshita T; Ishibashi M; Hoshino T
Eur J Radiol; 2012 Dec; 81(12):4179-84. PubMed ID: 22884163
[TBL] [Abstract][Full Text] [Related]
15. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
Fujimoto E; Kijima T; Kuribayashi K; Negi Y; Kanemura S; Mikami K; Doi H; Kitajima K; Nakano T
Expert Rev Anticancer Ther; 2017 Sep; 17(9):865-872. PubMed ID: 28594258
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.
Genestreti G; Moretti A; Piciucchi S; Tiseo M; Bersanelli M; Scarlattei M; Scarpi E; Dubini A; Matteucci F; Sanna S
Technol Cancer Res Treat; 2012 Apr; 11(2):163-7. PubMed ID: 22335410
[TBL] [Abstract][Full Text] [Related]
17. Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy.
Moon SH; Cho SH; Park LC; Ji JH; Sun JM; Ahn JS; Park K; Choi JY; Ahn MJ
Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1005-13. PubMed ID: 23595109
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of metabolic parameters measured by
Chang H; Lee SJ; Lim J; Lee JS; Kim YJ; Lee WW
J Cancer Res Clin Oncol; 2019 May; 145(5):1361-1367. PubMed ID: 30900157
[TBL] [Abstract][Full Text] [Related]
19. Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma.
Pilling J; Dartnell JA; Lang-Lazdunski L
Thorac Cardiovasc Surg; 2010 Jun; 58(4):215-9. PubMed ID: 20514576
[TBL] [Abstract][Full Text] [Related]
20. Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.
Fodor A; Broggi S; Incerti E; Dell'Oca I; Fiorino C; Samanes Gajate AM; Pasetti M; Cattaneo MG; Passoni P; Gianolli L; Calandrino R; Picchio M; Di Muzio N
Clin Lung Cancer; 2019 Jan; 20(1):e29-e38. PubMed ID: 30253920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
